For research use only. Not for therapeutic Use.
RR-RJW100（Cat No.:I042847）is a selective inhibitor of the protein kinase CK2 (casein kinase 2), which is involved in regulating various cellular processes, including cell growth, survival, and differentiation. CK2 has been implicated in cancer, inflammation, and neurodegenerative diseases due to its overexpression or dysregulation. By inhibiting CK2, RR-RJW100 aims to disrupt these abnormal signaling pathways, offering potential therapeutic benefits in treating cancers and other diseases where CK2 plays a critical role. RR-RJW100 is currently undergoing research to evaluate its efficacy and safety in preclinical and clinical settings.
| Synonyms | (1R,3aR,6aR)-5-hexyl-4-phenyl-3a-(1-phenylethenyl)-2,3,6,6a-tetrahydro-1H-pentalen-1-ol |
| Molecular Formula | C28H34O |
| Purity | ≥95% |
| IUPAC Name | (1R,3aR,6aR)-5-hexyl-4-phenyl-3a-(1-phenylethenyl)-2,3,6,6a-tetrahydro-1H-pentalen-1-ol |
| InChI | InChI=1S/C28H34O/c1-3-4-5-8-17-24-20-25-26(29)18-19-28(25,21(2)22-13-9-6-10-14-22)27(24)23-15-11-7-12-16-23/h6-7,9-16,25-26,29H,2-5,8,17-20H2,1H3/t25-,26+,28-/m0/s1 |
| InChIKey | ZFXMYHPLTQTTFW-REUBFRLUSA-N |
| SMILES | CCCCCCC1=C([C@@]2(CC[C@H]([C@@H]2C1)O)C(=C)C3=CC=CC=C3)C4=CC=CC=C4 |
